← Back to Search

mTOR inhibitor

Everolimus for Kidney Failure

Phase 3
Waitlist Available
Led By Chandrashekhar Kubal, MD
Research Sponsored by Indiana University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 36 months post-transplant
Awards & highlights

Study Summary

This trial is comparing the long-term renal function of patients who receive Everolimus monotherapy versus Tacrolimus monotherapy.

Eligible Conditions
  • Kidney Failure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~36 months post-transplant
This trial's timeline: 3 weeks for screening, Varies for treatment, and 36 months post-transplant for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Long-Term Renal Function With Everolimus Monotherapy
Long-Term Renal Function With Tacrolimus Monotherapy

Side effects data

From 2017 Phase 4 trial • 60 Patients • NCT02096107
20%
Hospitalization
20%
Immunosuppression held or modified
10%
Infections
100%
80%
60%
40%
20%
0%
Study treatment Arm
Standard of Care
Low Intensity Tacrolimus

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Study ArmExperimental Treatment1 Intervention
Everolimus monotherapy maintenance immunosuppression
Group II: Control ArmActive Control1 Intervention
Tacrolimus as maintenance immunosuppression
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Everolimus
FDA approved

Find a Location

Who is running the clinical trial?

Indiana UniversityLead Sponsor
980 Previous Clinical Trials
981,748 Total Patients Enrolled
2 Trials studying Kidney Failure
4 Patients Enrolled for Kidney Failure
Chandrashekhar Kubal, MDPrincipal Investigator - Indiana University
Indiana University
1 Previous Clinical Trials
4 Total Patients Enrolled
1 Trials studying Kidney Failure
4 Patients Enrolled for Kidney Failure

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How is Everolimus most often used?

"Everolimus has a wide range of potential applications, most commonly treating kidney transplant rejection and psoriasis. It can also be used to manage waldenstrom macroglobulinemia and certain types of lung conditions."

Answered by AI

Could you tell me how many people are part of this trial?

"That is correct. The listing on clinicaltrials.gov indicates that the investigators are currently looking for participants. This particular trial was first announced on May 9th, 2019 and updated September 19th, 2019. Up to 104 patients will be enrolled at a single location."

Answered by AI

Does Everolimus have a history of efficacy in other medical investigations?

"There are 246 ongoing studies researching Everolimus, with 31 trials in Phase 3. Many of the studies for Everolimus are based in Philadelphia, Pennsylvania, but there are clinical trials happening in 4856 locations around the world."

Answered by AI

Does Everolimus present any considerable health risks?

"The safety of Everolimus has been well-documented in past Phase 3 trials, and so it received a score of 3."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Everolimus Monotherapy as Immunosuppression After Liver Transplant
Chandrashekhar Kubal 2019. "Everolimus Monotherapy as Immunosuppression After Liver Transplant". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04063865.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top